Akero Therapeutics (AKRO) 2025 Conference June 04, 2025 11:45 AM ET Speaker0 All right. Good morning, everyone. Welcome to the next session here at the twenty twenty five Jefferies Healthcare Conference. I am absolutely pleased to have here with us today the CEO of As many of you know, Acero, has had a phenomenal, last couple of years, obviously, with recent, positive, F4 cirrhosis data, amongst other things, and executing on a phase three program. And so, and I might as well just say speculated as a as a p ...

Akero Therapeutics (AKRO) 2025 Conference May 13, 2025 04:40 PM ET Speaker0 And I'm very pleased to have joined me in our first slot of the afternoon session, Andrew Chang, CEO of Vaccaro. Thank you so much for joining us. Speaker1 Thank you for having us, Jason. Well, perfect. Speaker0 Maybe just to start broadly to provide a little context for those newer to the story, Can you describe the role of FGF21 in the pathogenesis of liver fibrosis? Kind of acknowledging that it is somewhat early, but what are so ...